세계의 암 진단 시장 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2025-2032년)

Cancer Diagnostics Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032

US $ 4,995 ￦ 6,919,000

Unprintable PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 복사, 인쇄가 불가능합니다.

US $ 7,295 ￦ 10,105,000

PDF & Excel (Multi User License)

PDF, Excel 보고서를 동일 기업 내 5명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

US $ 8,495 ￦ 11,768,000

PDF & Excel (Corporate User License)

PDF, Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

한글목차

주요 조사 결과

• 암 진단 시장 규모 : 1,378억 달러(2025년)
• 예상 시장 규모 : 2,227억 달러(2032년)
• 세계 시장 성장률: 7.1%(2025-2032년 CAGR)

암 진단 시장 - 보고서 범위

암 진단에는 암을 조기에 발견하고 치료 성과와 생존율을 향상시키기 위한 다양한 도구, 기술 및 시술이 포함됩니다. 이 시장에는 영상 기술, 생검 기술, 종양 바이오마커, 분자진단, 현장 검사 시스템 등이 포함됩니다. 이러한 진단은 병원, 병리검사실, 전문 클리닉 등에서 유방암, 폐암, 대장암, 전립선암, 자궁경부암, 혈액암 등 다양한 유형의 암을 감지하는 데 활용되고 있습니다. 시장 성장의 원동력은 전 세계 암 발병률 증가, 조기 발견에 대한 인식 증가, 정밀 진단 및 개인 맞춤형 의료의 발전입니다.

시장 성장 촉진요인

세계 암 진단 시장은 고령화, 생활습관 변화, 환경적 요인으로 인한 전 세계 암 발병률 증가 등 여러 요인에 힘입어 성장하고 있습니다. 첨단 진단 기술을 통한 조기 발견은 생존율을 크게 향상시켜 혁신적인 솔루션에 대한 수요를 촉진하고 있습니다. 차세대 염기서열 분석(NGS), 액체 생검, AI를 활용한 영상 진단과 같은 기술 발전은 암 발견을 변화시키고 최소침습적 접근법을 촉진하고 있습니다. 정부의 암 검진 프로그램 지원, 의료비 증가, 종양학에서 동반 진단의 채택 확대는 시장 확대를 더욱 촉진하고 있습니다.

시장 성장 억제요인

암 진단 시장은 견조한 성장이 예상되지만, 특히 첨단 분자 및 유전체 검사의 높은 진단 비용 등 여러 가지 과제에 직면해 있습니다. 중저소득 국가에서는 진단 시설에 대한 접근성이 제한되어 있어 조기 발견과 치료를 방해하고 있습니다. 또한, 암의 이질성과 유전자 변이의 복잡성으로 인해 지속적인 기술 혁신과 임상 검증이 필요하며, 이는 개발 비용과 출시 기간을 증가시킵니다. 규제적 장애물과 상환 제약도 새로운 진단 기술의 상업적 실현 가능성에 영향을 미칩니다. 이러한 문제를 해결하기 위해서는 범부처적 협력과 합리적인 가격의 확장 가능한 진단 플랫폼에 대한 집중적인 투자가 필요합니다.

시장 기회

암 진단 시장은 기술 혁신과 진단에서 AI와 머신러닝의 역할 확대로 인해 큰 성장 기회를 제공합니다. 비침습적 실시간암 모니터링 도구로서 액체생검이 부상하며 지지를 받고 있습니다. 바이오마커 탐색, 빅데이터 분석의 통합, 멀티플렉스 진단 플랫폼 개발에 대한 투자 증가는 개인화된 조기 암 진단을 위한 새로운 길을 열어줄 것입니다. 또한, 재택 암 검진 도구와 모바일 진단에 대한 관심이 높아짐에 따라, 특히 원격지나 의료서비스가 부족한 지역에서 접근성과 순응도가 향상될 수 있습니다.

이 보고서는 세계 암 진단 시장을 조사했으며, 성장 촉진요인, 동향, 기회, 과제 등 시장 역학에 대한 상세한 분석을 제공합니다.

목차

제1장 주요 요약

제2장 시장 개요

• 시장 범위와 정의
• 시장 역학
  • 성장 촉진요인
  • 성장 억제요인
  • 기회
  • 과제
  • 주요 동향
• COVID-19의 영향 분석
• 예측 요인 - 관련성과 영향

제3장 부가가치 인사이트

• 밸류체인 분석
• 진단 검사 채택/사용 분석
• 암 유병률과 이환율
• 암 진단에 관련된 정부 이니셔티브와 자금 제공
• 주요 시장 기업
• 규제 상황
• PESTLE 분석
• Porter의 Five Forces 분석
• 소비자 행동 분석

제4장 세계의의 암 진단 시장 전망

• 주요 하이라이트
  • 시장 규모와 전년대비 성장
  • 절대적 매출 기회
• 시장 규모 분석과 예측
  • 시장 규모 분석(2019년-2024년)
  • 현재 시장 규모 분석과 예측(2025년-2032년)
• 세계의 암 진단 시장 전망 : 진단 검사
  • 시장 규모 분석 : 진단 검사별(2019년-2024년)
  • 현재 시장 규모 분석과 예측 : 진단 검사별(2025년-2032년)
  • 시장의 매력 분석 : 진단 검사
• 세계의 암 진단 시장 전망 : 형태
  • 시장 규모 분석 : 형태별(2019년-2024년)
  • 현재 시장 규모 분석과 예측 : 형태별(2025년-2032년)
  • 시장의 매력 분석 : 형태
• 세계의 암 진단 시장 전망 : 용도
  • 시장 규모 분석 : 용도별(2019년-2024년)
  • 현재 시장 규모 분석과 예측 : 용도별(2025년-2032년)
  • 시장의 매력 분석 : 용도
• 세계의 암 진단 시장 전망 : 최종 용도
  • 시장 규모 분석 : 최종 용도별(2019년-2024년)
  • 현재 시장 규모 분석과 예측 : 최종 용도별(2025년-2032년)
  • 시장의 매력 분석 : 최종 용도

제5장 세계의 암 진단 시장 전망 지역

• 시장 규모 분석 : 지역별(2019년-2024년)
• 현재 시장 규모 분석과 예측 : 지역별(2025년-2032년)
  • 북미
  • 라틴아메리카
  • 유럽
  • 동아시아
  • 남아시아 및 오세아니아
  • 중동 및 아프리카
• 시장의 매력 분석 : 지역

제6장 북미의 암 진단 시장 전망

제7장 유럽의 암 진단 시장 전망

제8장 동아시아의 암 진단 시장 전망

제9장 남아시아 및 오세아니아의 암 진단 시장 전망

제10장 라틴아메리카의 암 진단 시장 전망

제11장 중동 및 아프리카의 암 진단 시장 전망

제12장 경쟁 구도

• 시장 점유율 분석(2025년)
• 시장 구조
  • 경쟁 강도 맵 : 시장별
  • 경쟁 대시보드
• 기업 개요(상세 - 개요, 재무, 전략, 최근 발전)
  • F. Hoffmann-La Roche Ltd
  • Thermo Fisher Scientific Inc.
  • Abbott Laboratories
  • Illumina Inc.
  • bioMerieux SA
  • Qiagen
  • Siemens Healthineers
  • GE Healthcare
  • Hologic Inc.
  • Agilent Technologies Inc.
  • Becton, Dickinson and Company(BD)
  • Myriad Genetics Inc.
  • AstraZeneca
  • Regeneron
  • Novartis
  • BIO-RAD LABORATORIES
  • CANCER DIAGNOSTICS INC.
  • QUIDEL CORPORATION
  • Koninklijke Philips N.V.(Philips)
  • 기타

제13장 부록

LSH

영문 목차

영문목차

Persistence Market Research has recently released a comprehensive report on the worldwide market for cancer diagnostics. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global cancer diagnostics market from 2025 to 2032.

Key Insights:

• Cancer Diagnostics Market Size (2025E): USD 137.8 Billion
• Projected Market Value (2032F): USD 222.7 Billion
• Global Market Growth Rate (CAGR 2025 to 2032): 7.1%

Cancer Diagnostics Market - Report Scope:

Cancer diagnostics encompass a wide range of tools, technologies, and procedures aimed at detecting cancer at early stages to improve treatment outcomes and survival rates. The market includes imaging technologies, biopsy techniques, tumor biomarkers, molecular diagnostics, and point-of-care testing systems. These diagnostics are utilized across hospitals, pathology labs, and specialty clinics to detect various types of cancer, including breast, lung, colorectal, prostate, cervical, and blood cancers. Market growth is driven by the rising global cancer burden, increasing awareness about early detection, and ongoing advancements in precision diagnostics and personalized medicine.

Market Growth Drivers:

The global cancer diagnostics market is propelled by multiple factors, notably the increasing incidence of cancer worldwide due to aging populations, lifestyle changes, and environmental factors. Early detection through advanced diagnostic technologies significantly improves survival rates, driving demand for innovative solutions. Technological advancements such as next-generation sequencing (NGS), liquid biopsy, and AI-powered diagnostic imaging are transforming cancer detection and facilitating minimally invasive approaches. Government initiatives supporting cancer screening programs, rising healthcare expenditure, and the growing adoption of companion diagnostics in oncology further stimulate market expansion.

Market Restraints:

Despite robust growth prospects, the cancer diagnostics market faces several challenges, including high diagnostic costs, especially for advanced molecular and genomic tests. Limited access to diagnostic facilities in low- and middle-income countries impedes early detection and treatment. Additionally, the complexity of cancer heterogeneity and evolving genetic mutations requires continuous innovation and clinical validation, raising development costs and time-to-market. Regulatory hurdles and reimbursement constraints also impact the commercial viability of emerging diagnostic technologies. Addressing these challenges necessitates cross-sector collaboration and targeted investment in affordable, scalable diagnostic platforms.

Market Opportunities:

The cancer diagnostics market presents significant growth opportunities driven by technological innovations and the expanding role of artificial intelligence and machine learning in diagnostics. The emergence of liquid biopsy as a non-invasive, real-time cancer monitoring tool is gaining traction. Growing investments in biomarker discovery, integration of big data analytics, and the development of multiplex diagnostic platforms open new avenues for personalized and early-stage cancer diagnostics. Moreover, increased focus on home-based cancer screening tools and mobile diagnostics can improve accessibility and compliance, especially in remote or underserved areas.

Key Questions Answered in the Report:

• What are the key factors contributing to the global growth of the cancer diagnostics market?
• Which diagnostic technologies and cancer types are driving market demand across various regions?
• How are innovations in molecular diagnostics and AI reshaping the competitive dynamics of the market?
• Who are the leading players in the cancer diagnostics market, and what strategies are they adopting for market leadership?
• What are the emerging trends and future opportunities in the global cancer diagnostics landscape?

Competitive Intelligence and Business Strategy:

Leading players in the global cancer diagnostics market, such as F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, and Becton, Dickinson and Company, are actively investing in R&D, strategic collaborations, and acquisitions to enhance their diagnostic portfolios. These companies focus on developing comprehensive cancer detection platforms combining genetic, proteomic, and imaging-based technologies. Collaborations with pharmaceutical firms for companion diagnostics and personalized treatment regimens are key strategic moves. In addition, companies are expanding their geographic presence through partnerships with local healthcare providers and governments to address the rising demand for cancer diagnostics across emerging markets.

Key Companies Profiled:

• F. Hoffmann-La Roche Ltd
• Thermo Fisher Scientific Inc.
• Abbott Laboratories
• Illumina Inc.
• bioMerieux SA
• Qiagen
• Siemens Healthineers
• GE Healthcare
• Hologic Inc.
• Koninklijke Philips N.V. (Philips)
• Agilent Technologies Inc.
• Becton, Dickinson and Company (BD)
• Myriad Genetics Inc.
• AstraZeneca
• Regeneron
• Novartis
• Bio-Rad Laboratories
• Cancer Diagnostics Inc.
• Quidel Corporation
• Others

Market Segmentation

By Diagnostic Test

• Biomarker Test
• Prostate-Specific Antigen (PSA)
• Circulating Tumor Cells (CTC)
• Alpha-Fetoprotein (AFP)
• Cancer Antigen 125 (CA-125)
• HER2
• Other
• Imaging Technology
• Magnetic Resonance Imaging (MRI)
• Computed Tomography (CT)
• Positron Emission Tomography (PET)
• Mammography
• Others
• Endoscopy
• Colonoscopy
• Biopsy
• Others

By Application

• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Melanoma Cancer
• Blood Cancer
• Ovarian Cancer
• Other

By End-Use

• Hospitals
• Diagnostic Laboratories
• Cancer Research Institutes
• Ambulatory Surgical Centers

By Region

• North America
• Europe
• East Asia
• South Asia and Oceania
• Latin America
• Middle East and Africa

Table of Contents

1. Executive Summary

• 1.1. Global Cancer Diagnostics Market Snapshot, 2025-2032
• 1.2. Market Opportunity Assessment, 2025-2032, US$ Bn
• 1.3. Key Market Trends
• 1.4. Future Market Projections
• 1.5. Premium Market Insights
• 1.6. Industry Developments and Key Market Events
• 1.7. PMR Analysis and Recommendations

2. Market Overview

• 2.1. Market Scope and Definition
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Opportunity
  • 2.2.4. Challenges
  • 2.2.5. Key Trends
• 2.3. COVID-19 Impact Analysis
• 2.4. Forecast Factors - Relevance and Impact

3. Value Added Insights

• 3.1. Value Chain Analysis
• 3.2. Diagnostic Test Adoption / Usage Analysis
• 3.3. Prevalence & Incidence of Cancer
• 3.4. Government Initiatives & Funding in Cancer Diagnostics
• 3.5. Key Market Players
• 3.6. Regulatory Landscape
• 3.7. PESTLE Analysis
• 3.8. Porter's Five Force Analysis
• 3.9. Consumer Behavior Analysis

4. Global Cancer Diagnostics Market Outlook

• 4.1. Key Highlights
  • 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
  • 4.1.2. Absolute $ Opportunity
• 4.2. Market Size (US$ Bn) Analysis and Forecast
  • 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2024
  • 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2025-2032
• 4.3. Global Cancer Diagnostics Market Outlook Diagnostic Test
  • 4.3.1. Historical Market Size (US$ Bn) Analysis, By Diagnostic Test, 2019-2024
  • 4.3.2. Current Market Size (US$ Bn) Analysis and Forecast, By Diagnostic Test, 2025-2032
    • 4.3.2.1. Biomarker Test
      • 4.3.2.1.1. Prostate-Specific Antigen (PSA)
      • 4.3.2.1.2. Circulating Tumor Cells (CTC)
      • 4.3.2.1.3. Alpha-Fetoprotein (AFP)
      • 4.3.2.1.4. Cancer Antigen 125 (CA-125)
      • 4.3.2.1.5. HER2
      • 4.3.2.1.6. Other
    • 4.3.2.2. Imaging Technology
      • 4.3.2.2.1. Magnetic Resonance Imaging (MRI)
      • 4.3.2.2.2. Computed Tomography (CT)
      • 4.3.2.2.3. Positron Emission Tomography (PET)
      • 4.3.2.2.4. Mammography
      • 4.3.2.2.5. Others
    • 4.3.2.3. Endoscopy
    • 4.3.2.4. Colonoscopy
    • 4.3.2.5. Biopsy
    • 4.3.2.6. Others
  • 4.3.3. Market Attractiveness Analysis: Diagnostic Test
• 4.4. Global Cancer Diagnostics Market Outlook Form
  • 4.4.1. Historical Market Size (US$ Bn) Analysis, By Form, 2019-2024
  • 4.4.2. Current Market Size (US$ Bn) Analysis and Forecast, By Form, 2025-2032
    • 4.4.2.1. Isolates
    • 4.4.2.2. Concentrates
    • 4.4.2.3. Hydrolysates
  • 4.4.3. Market Attractiveness Analysis: Form
• 4.5. Global Cancer Diagnostics Market Outlook Application
  • 4.5.1. Historical Market Size (US$ Bn) Analysis, By Application, 2019-2024
  • 4.5.2. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 4.5.2.1. Lung Cancer
    • 4.5.2.2. Breast Cancer
    • 4.5.2.3. Prostate Cancer
    • 4.5.2.4. Colorectal Cancer
    • 4.5.2.5. Melanoma Cancer
    • 4.5.2.6. Blood Cancer
    • 4.5.2.7. Ovarian Cancer
    • 4.5.2.8. Other
  • 4.5.3. Market Attractiveness Analysis: Application
• 4.6. Global Cancer Diagnostics Market Outlook End-use
  • 4.6.1. Historical Market Size (US$ Bn) Analysis, By End-use, 2019-2024
  • 4.6.2. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2025-2032
    • 4.6.2.1. Hospitals
    • 4.6.2.2. Diagnostic Laboratories
    • 4.6.2.3. Cancer Research Institutes
    • 4.6.2.4. Ambulatory Surgical Centers
  • 4.6.3. Market Attractiveness Analysis: End-use

5. Global Cancer Diagnostics Market Outlook Region

• 5.1. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2024
• 5.2. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2025-2032
  • 5.2.1. North America
  • 5.2.2. Latin America
  • 5.2.3. Europe
  • 5.2.4. East Asia
  • 5.2.5. South Asia and Oceania
  • 5.2.6. Middle East & Africa
• 5.3. Market Attractiveness Analysis: Region

6. North America Cancer Diagnostics Market Outlook

• 6.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
  • 6.1.1. By Country
  • 6.1.2. By Diagnostic Test
  • 6.1.3. By Application
  • 6.1.4. By End-use
• 6.2. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
  • 6.2.1. U.S.
  • 6.2.2. Canada
• 6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Diagnostic Test, 2025-2032
  • 6.3.1. Biomarker Test
    • 6.3.1.1. Prostate-Specific Antigen (PSA)
    • 6.3.1.2. Circulating Tumor Cells (CTC)
    • 6.3.1.3. Alpha-Fetoprotein (AFP)
    • 6.3.1.4. Cancer Antigen 125 (CA-125)
    • 6.3.1.5. HER2
    • 6.3.1.6. Other
  • 6.3.2. Imaging Technology
    • 6.3.2.1. Magnetic Resonance Imaging (MRI)
    • 6.3.2.2. Computed Tomography (CT)
    • 6.3.2.3. Positron Emission Tomography (PET)
    • 6.3.2.4. Mammography
    • 6.3.2.5. Others
  • 6.3.3. Endoscopy
  • 6.3.4. Colonoscopy
  • 6.3.5. Biopsy
  • 6.3.6. Others
• 6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
  • 6.4.1. Lung Cancer
  • 6.4.2. Breast Cancer
  • 6.4.3. Prostate Cancer
  • 6.4.4. Colorectal Cancer
  • 6.4.5. Melanoma Cancer
  • 6.4.6. Blood Cancer
  • 6.4.7. Ovarian Cancer
  • 6.4.8. Other
• 6.5. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2025-2032
  • 6.5.1. Hospitals
  • 6.5.2. Diagnostic Laboratories
  • 6.5.3. Cancer Research Institutes
  • 6.5.4. Ambulatory Surgical Centers
• 6.6. Market Attractiveness Analysis

7. Europe Cancer Diagnostics Market Outlook

• 7.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
  • 7.1.1. By Country
  • 7.1.2. By Diagnostic Test
  • 7.1.3. By Form
  • 7.1.4. By Application
  • 7.1.5. By End-use
• 7.2. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
  • 7.2.1. Germany
  • 7.2.2. France
  • 7.2.3. U.K.
  • 7.2.4. Italy
  • 7.2.5. Spain
  • 7.2.6. Russia
  • 7.2.7. Rest of Europe
• 7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Diagnostic Test, 2025-2032
  • 7.3.1. Biomarker Test
    • 7.3.1.1. Prostate-Specific Antigen (PSA)
    • 7.3.1.2. Circulating Tumor Cells (CTC)
    • 7.3.1.3. Alpha-Fetoprotein (AFP)
    • 7.3.1.4. Cancer Antigen 125 (CA-125)
    • 7.3.1.5. HER2
    • 7.3.1.6. Other
  • 7.3.2. Imaging Technology
    • 7.3.2.1. Magnetic Resonance Imaging (MRI)
    • 7.3.2.2. Computed Tomography (CT)
    • 7.3.2.3. Positron Emission Tomography (PET)
    • 7.3.2.4. Mammography
    • 7.3.2.5. Others
  • 7.3.3. Endoscopy
  • 7.3.4. Colonoscopy
  • 7.3.5. Biopsy
  • 7.3.6. Others
• 7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
  • 7.4.1. Lung Cancer
  • 7.4.2. Breast Cancer
  • 7.4.3. Prostate Cancer
  • 7.4.4. Colorectal Cancer
  • 7.4.5. Melanoma Cancer
  • 7.4.6. Blood Cancer
  • 7.4.7. Ovarian Cancer
  • 7.4.8. Other
• 7.5. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2025-2032
  • 7.5.1. Hospitals
  • 7.5.2. Diagnostic Laboratories
  • 7.5.3. Cancer Research Institutes
  • 7.5.4. Ambulatory Surgical Centers
• 7.6. Market Attractiveness Analysis

8. East Asia Cancer Diagnostics Market Outlook

• 8.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
  • 8.1.1. By Country
  • 8.1.2. By Diagnostic Test
  • 8.1.3. By Application
  • 8.1.4. By End-use
• 8.2. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
  • 8.2.1. China
  • 8.2.2. Japan
  • 8.2.3. South Korea
• 8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Diagnostic Test, 2025-2032
  • 8.3.1. Biomarker Test
    • 8.3.1.1. Prostate-Specific Antigen (PSA)
    • 8.3.1.2. Circulating Tumor Cells (CTC)
    • 8.3.1.3. Alpha-Fetoprotein (AFP)
    • 8.3.1.4. Cancer Antigen 125 (CA-125)
    • 8.3.1.5. HER2
    • 8.3.1.6. Other
  • 8.3.2. Imaging Technology
    • 8.3.2.1. Magnetic Resonance Imaging (MRI)
    • 8.3.2.2. Computed Tomography (CT)
    • 8.3.2.3. Positron Emission Tomography (PET)
    • 8.3.2.4. Mammography
    • 8.3.2.5. Others
  • 8.3.3. Endoscopy
  • 8.3.4. Colonoscopy
  • 8.3.5. Biopsy
  • 8.3.6. Others
• 8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
  • 8.4.1. Lung Cancer
  • 8.4.2. Breast Cancer
  • 8.4.3. Prostate Cancer
  • 8.4.4. Colorectal Cancer
  • 8.4.5. Melanoma Cancer
  • 8.4.6. Blood Cancer
  • 8.4.7. Ovarian Cancer
  • 8.4.8. Other
• 8.5. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2025-2032
  • 8.5.1. Hospitals
  • 8.5.2. Diagnostic Laboratories
  • 8.5.3. Cancer Research Institutes
  • 8.5.4. Ambulatory Surgical Centers
• 8.6. Market Attractiveness Analysis

9. South Asia & Oceania Cancer Diagnostics Market Outlook

• 9.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
  • 9.1.1. By Country
  • 9.1.2. By Diagnostic Test
  • 9.1.3. By Application
  • 9.1.4. By End-use
• 9.2. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
  • 9.2.1. India
  • 9.2.2. Indonesia
  • 9.2.3. Thailand
  • 9.2.4. Singapore
  • 9.2.5. ANZ
  • 9.2.6. Rest of South Asia & Oceania
• 9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Diagnostic Test, 2025-2032
  • 9.3.1. Biomarker Test
    • 9.3.1.1. Prostate-Specific Antigen (PSA)
    • 9.3.1.2. Circulating Tumor Cells (CTC)
    • 9.3.1.3. Alpha-Fetoprotein (AFP)
    • 9.3.1.4. Cancer Antigen 125 (CA-125)
    • 9.3.1.5. HER2
    • 9.3.1.6. Other
  • 9.3.2. Imaging Technology
    • 9.3.2.1. Magnetic Resonance Imaging (MRI)
    • 9.3.2.2. Computed Tomography (CT)
    • 9.3.2.3. Positron Emission Tomography (PET)
    • 9.3.2.4. Mammography
    • 9.3.2.5. Others
  • 9.3.3. Endoscopy
  • 9.3.4. Colonoscopy
  • 9.3.5. Biopsy
  • 9.3.6. Others
• 9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
  • 9.4.1. Lung Cancer
  • 9.4.2. Breast Cancer
  • 9.4.3. Prostate Cancer
  • 9.4.4. Colorectal Cancer
  • 9.4.5. Melanoma Cancer
  • 9.4.6. Blood Cancer
  • 9.4.7. Ovarian Cancer
  • 9.4.8. Other
• 9.5. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2025-2032
  • 9.5.1. Hospitals
  • 9.5.2. Diagnostic Laboratories
  • 9.5.3. Cancer Research Institutes
  • 9.5.4. Ambulatory Surgical Centers
• 9.6. Market Attractiveness Analysis

10. Latin America Cancer Diagnostics Market Outlook

• 10.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
  • 10.1.1. By Country
  • 10.1.2. By Diagnostic Test
  • 10.1.3. By Application
  • 10.1.4. By End-use
• 10.2. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
  • 10.2.1. Brazil
  • 10.2.2. Mexico
  • 10.2.3. Rest of Latin America
• 10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Diagnostic Test, 2025-2032
  • 10.3.1. Biomarker Test
    • 10.3.1.1. Prostate-Specific Antigen (PSA)
    • 10.3.1.2. Circulating Tumor Cells (CTC)
    • 10.3.1.3. Alpha-Fetoprotein (AFP)
    • 10.3.1.4. Cancer Antigen 125 (CA-125)
    • 10.3.1.5. HER2
    • 10.3.1.6. Other
  • 10.3.2. Imaging Technology
    • 10.3.2.1. Magnetic Resonance Imaging (MRI)
    • 10.3.2.2. Computed Tomography (CT)
    • 10.3.2.3. Positron Emission Tomography (PET)
    • 10.3.2.4. Mammography
    • 10.3.2.5. Others
  • 10.3.3. Endoscopy
  • 10.3.4. Colonoscopy
  • 10.3.5. Biopsy
  • 10.3.6. Others
• 10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
  • 10.4.1. Lung Cancer
  • 10.4.2. Breast Cancer
  • 10.4.3. Prostate Cancer
  • 10.4.4. Colorectal Cancer
  • 10.4.5. Melanoma Cancer
  • 10.4.6. Blood Cancer
  • 10.4.7. Ovarian Cancer
  • 10.4.8. Other
• 10.5. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2025-2032
  • 10.5.1. Hospitals
  • 10.5.2. Diagnostic Laboratories
  • 10.5.3. Cancer Research Institutes
  • 10.5.4. Ambulatory Surgical Centers
• 10.6. Market Attractiveness Analysis

11. Middle East & Africa Cancer Diagnostics Market Outlook

• 11.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
  • 11.1.1. By Country
  • 11.1.2. By Diagnostic Test
  • 11.1.3. By Application
  • 11.1.4. By End-use
• 11.2. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
  • 11.2.1. GCC Countries
  • 11.2.2. Egypt
  • 11.2.3. South Africa
  • 11.2.4. Northern Africa
  • 11.2.5. Rest of Middle East & Africa
• 11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Diagnostic Test, 2025-2032
  • 11.3.1. Biomarker Test
    • 11.3.1.1. Prostate-Specific Antigen (PSA)
    • 11.3.1.2. Circulating Tumor Cells (CTC)
    • 11.3.1.3. Alpha-Fetoprotein (AFP)
    • 11.3.1.4. Cancer Antigen 125 (CA-125)
    • 11.3.1.5. HER2
    • 11.3.1.6. Other
  • 11.3.2. Imaging Technology
    • 11.3.2.1. Magnetic Resonance Imaging (MRI)
    • 11.3.2.2. Computed Tomography (CT)
    • 11.3.2.3. Positron Emission Tomography (PET)
    • 11.3.2.4. Mammography
    • 11.3.2.5. Others
  • 11.3.3. Endoscopy
  • 11.3.4. Colonoscopy
  • 11.3.5. Biopsy
  • 11.3.6. Others
• 11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
  • 11.4.1. Lung Cancer
  • 11.4.2. Breast Cancer
  • 11.4.3. Prostate Cancer
  • 11.4.4. Colorectal Cancer
  • 11.4.5. Melanoma Cancer
  • 11.4.6. Blood Cancer
  • 11.4.7. Ovarian Cancer
  • 11.4.8. Other
• 11.5. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2025-2032
  • 11.5.1. Hospitals
  • 11.5.2. Diagnostic Laboratories
  • 11.5.3. Cancer Research Institutes
  • 11.5.4. Ambulatory Surgical Centers
• 11.6. Market Attractiveness Analysis

12. Competition Landscape

• 12.1. Market Share Analysis, 2025
• 12.2. Market Structure
  • 12.2.1. Competition Intensity Mapping by Market
  • 12.2.2. Competition Dashboard
• 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  • 12.3.1. F. Hoffmann-La Roche Ltd
    • 12.3.1.1. Overview
    • 12.3.1.2. Segments and Sources
    • 12.3.1.3. Key Financials
    • 12.3.1.4. Market Developments
    • 12.3.1.5. Market Strategy
  • 12.3.2. Thermo Fisher Scientific Inc.
  • 12.3.3. Abbott Laboratories
  • 12.3.4. Illumina Inc.
  • 12.3.5. bioMerieux SA
  • 12.3.6. Qiagen
  • 12.3.7. Siemens Healthineers
  • 12.3.8. GE Healthcare
  • 12.3.9. Hologic Inc.
  • 12.3.10. Agilent Technologies Inc.
  • 12.3.11. Becton, Dickinson and Company (BD)
  • 12.3.12. Myriad Genetics Inc.
  • 12.3.13. AstraZeneca
  • 12.3.14. Regeneron
  • 12.3.15. Novartis
  • 12.3.16. BIO-RAD LABORATORIES
  • 12.3.17. CANCER DIAGNOSTICS INC.
  • 12.3.18. QUIDEL CORPORATION
  • 12.3.19. Koninklijke Philips N.V. (Philips)
  • 12.3.20. Others

13. Appendix

• 13.1. Research Methodology
• 13.2. Research Assumptions
• 13.3. Acronyms and Abbreviations

관련자료